Evidence map›Paper›PMID 32447545›Full record

ArticleNeurology and therapy2020

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies.

Timothy Smith, John H Krege, Suchitrita S Rathmann, Sherie A Dowsett, Ann Hake, Emel S M Nery, Brandy R Matthews, Erin G Doty

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02439320 phase3completednot on this map

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

TypeinterventionalSponsorEli Lilly and CompanyRan2015 to 2016Enrolled2,231ConditionsAcute MigraineArmsLasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses)
NCT02565186 phase3completednot on this map

An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

TypeinterventionalSponsorEli Lilly and CompanyRan2015 to 2019Enrolled2,171ConditionsMigraine DisordersArmsLasmiditan
NCT02605174 phase3completednot on this map

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

TypeinterventionalSponsorEli Lilly and CompanyRan2016 to 2017Enrolled3,005ConditionsMigraine With or Without AuraArmsLasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Timothy SmithStudyMetrix Research, St. Peters, MO, USA.
John H KregeEli Lilly and Company, Indianapolis, IN, USA.
Suchitrita S RathmannEli Lilly and Company, Indianapolis, IN, USA.
Sherie A DowsettEli Lilly and Company, Indianapolis, IN, USA.
Ann HakeEli Lilly and Company, Indianapolis, IN, USA.
Emel S M NeryEli Lilly and Company, Indianapolis, IN, USA.
Brandy R MatthewsEli Lilly and Company, Indianapolis, IN, USA.
Erin G DotyEli Lilly and Company, Indianapolis, IN, USA. doty_erin_gautier@lilly.com.
Eli Lilly (United States) · USIndiana University – Purdue University Indianapolis · USNeuroMetrix (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMigraine is associated with substantial functional impairment and affects many aspects of daily life.

methodsUsing data from SAMURAI and SPARTAN (double-blind, placebo-controlled, phase 3 studies) and GLADIATOR (an open-label, phase 3 study enrolling patients who had completed SAMURAI or SPARTAN), we assessed the effects of lasmiditan on migraine-related functional disability at multiple time points from 0.5 to 48 h post dose by asking patients to rate how much the migraine was interfering with normal activities. Pooled data from SAMURAI and SPARTAN (SAMURAI + SPARTAN) and data from GLADIATOR were analyzed using the intention-to-treat populations.

resultsFor SPARTAN + SAMURAI, significantly more patients who received lasmiditan at any dose versus placebo reported freedom from migraine-related functional disability at every timepoint from 2 h post dose, and this difference persisted to 48 h (p < 0.05). Significant differences from placebo in freedom from migraine-related functional disability commenced at 1 h post dose for lasmiditan 200 mg, 1.5 h for lasmiditan 100 mg, and 2 h for lasmiditan 50 mg. Findings from GLADIATOR supported those from SAMURAI + SPARTAN.

conclusionAll doses of lasmiditan resulted in an improvement in migraine-related functional disability that persisted to 48 h. In SAMURAI + SPARTAN, a significant difference from placebo was observed as early as 1 h post dose. TRIAL REGISTRATION AT CLINICALTRIALS.GOV: SAMURAI (NCT02439320), SPARTAN (NCT02605174), and GLADIATOR (NCT02565186).

Indexed as

DisabilityFunctionLasmiditanMigraine

Identifiers

PMID32447545
PMCPMC7606429
OpenAlexW3027380028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.